Helix BioPharma Corp. Appoints Thomas Mehrling, MD, PhD as New CEO to Lead Oncology Innovations
TL;DR
Dr. Mehrling, a seasoned Hemato-Oncologist and Pharmacologist, brings a track record of successful oncology businesses and transformative therapies.
Dr. Mehrling's appointment as CEO of Helix BioPharma Corp. signals a shift in leadership structure towards achieving ambitious clinical milestones.
The appointment of Dr. Mehrling as CEO aims to confront cancer's challenges with innovation, rapid decision-making, and delivering groundbreaking cancer drugs.
Dr. Mehrling plans to lead Helix in entering Phase II study for non-small cell lung cancer with L-DOS47, promising a game-changing assist to anti-cancer therapies.
Found this article helpful?
Share it with your network and spread the knowledge!
Helix BioPharma Corp., a clinical-stage oncology company, has announced the appointment of Dr. Thomas Mehrling as its new Chief Executive Officer. This strategic move is set to sharpen the company's focus on delivering transformative cancer therapies, with Dr. Mehrling's extensive experience in pharmaceutical oncology expected to play a pivotal role in achieving Helix's ambitious clinical milestones for 2025 and beyond.
Dr. Mehrling, a distinguished Hemato-Oncologist and Pharmacologist, brings over 20 years of experience in building successful global oncology businesses. His previous roles include significant contributions to Mundipharma International Ltd.'s European oncology business, where he was instrumental in introducing groundbreaking cancer drugs that achieved nearly USD 1 billion in sales. His leadership in founding Laevoroc Medical AG, which later collaborated with Helix, underscores his commitment to advancing oncology research and treatment.
Under Dr. Mehrling's leadership, Helix plans to initiate a Phase II study for L-DOS47 in combination with pembrolizumab for the treatment of non-small cell lung cancer, among other clinical milestones. The company is also preparing to finalize a financing deal to support these initiatives and expand its team of experts. Dr. Mehrling's vision for Helix emphasizes rapid innovation and decision-making to address the urgent challenges in cancer treatment, a mission he is deeply committed to.
Jacek Antas, transitioning from CEO to Chairman of the Company, expressed confidence in Dr. Mehrling's ability to lead Helix through its next phase of growth. Antas highlighted the importance of building a resilient and agile organization to deliver on the company's ambitious roadmap, with Dr. Mehrling's leadership and experience being key to this endeavor.
Helix BioPharma Corp. is at the forefront of developing novel therapies for hard-to-treat cancers, with a pipeline that includes innovative drug candidates like L-DOS47, a clinical-stage antibody-enzyme conjugate designed to target CEACAM6-expressing solid tumors. The company's commitment to advancing oncology research and treatment is reflected in its strategic appointments and clinical milestones, aiming to make a significant impact in the fight against cancer. For more information, visit https://www.helixbiopharma.com/.
Curated from NewMediaWire
